School of Biomolecular & Biomedical Science
Tel: Ext. 6766
Professor Rosier holds both a Doctorate in Pharmaceutical Sciences (Ghent University, Belgium) and a Doctorate in Management (Cranfield School of Management, UK). He was a Fulbright Scholar at Harvard University and was awarded a NATO research fellowship for research at MIT, Cambridge. As vice president pharmaceutical drug development at Johnson & Johnson he was instrumental in the development of TIBOZOLE®, LIVOSTIN®, PREPULSID®, SPORANOX®, RISPERDAL® and ERGAMISOL® and was awarded the Johnson & Johnson Leadership Award for outstanding and exceptional contribution to the development of PREZISTA® and INTELENCE® for the treatment of AIDS. In 2009, he became Chief Executive Officer of FORMAC Pharmaceuticals NV, a high technology drug delivery spin-off from the University of Leuven that uses silica based technology to increase the performance of drugs. Jan has extensive experience in attracting venture capital for high-risk academic spin-off biotech firms. His career has continuously taken place at the interface between university and industry. During his stay in industry he was engaged in academic biomedical research which resulted in scientific papers published in e.g. the International Journal of Pharmaceutics, European Journal of Biopharmaceutics, Electrophoresis, Journal of Chromatography Biomedical Applications, Nature etc. Since 2008, he teaches new drug development at the University of Leuven as a visiting professor. He also researches innovation in biotech firms as a Visiting Fellow at the Cranfield School of Management (UK). Jan is author of 'Global New Drug Development - An Introduction' (Wiley-Blackwell) and is currently writing his new book on the business of biotechnology. He is also a member of the Advisory Board of Incentives for Global Health's Health Impact Fund (healthimpactfund.org).
Honours and Awards
| Year: 2006.
Title: Leadership Award for the development of PREZISTA, a protease inhibitor for the treatment of AIDS
| Year: 2008.
Title: Leadership Award for the development of INTELENCE, a non-nucleoside reverse transcriptase inhibitor for the treatment of AIDS
| Year: 1985.
Title: NATO Research Fellowship (MIT)
| Year: 1985.
Title: Fulbright Scholarship for Research and Lecturing in the USA (Harvard)
|Committee : Advisory Board, Global Incentives for Health|
| Year 1985 Institution:
Qualification: PhD Subject: University of Ghent
| Year 1977 Institution:
Qualification: BSc(Pharm) Subject: Pharmaceutical Sciences at the University of Ghent
| Year 1984 Institution:
Qualification: MSc Subject: Human ecology at the Free University of Brussels
| Year 1980 Institution:
Qualification: MSc Subject: Pharmaceutical Sciences at the University of Ghent
|J. Rosier, M. Martens and J. Thomas (2013) An introduction to New Drug Development. London: Wiley Blackwell. [Details]|
Peer Reviewed Journals
|Jan Rosier and David O'Connell (2015) 'Nuances in the Entrepreneurship Training Toolbox'. Nature Biotechnology, 33 :133-135. [Details]|
|Rosier J., Billemont G., Van Peteghem C., Vanhoorne M., Grosjean R. and Van De Walle E. (1984) 'The relationship between the iodine-azide test and the TTCA-test for exposure to carbon disulfide'. British journal of industrial medicine, 17 :412. [Details]|
|Rosier J. and Van Peteghem C. (1984) 'The determination of toxicologically important partition coefficients of carbon disulfide by means of the vial equilibration method'. British journal of industrial medicine, 44 :212. [Details]|
|Rosier J. (1987) 'A fast micropreparative reversed phase HPLC purification procedure for (G-3H)- benzo(a)pyrene and 3-(6-14C)-methylcholanthrene'. Journal of Chromatography, 10 :2105. [Details]|
|Rosier J. and Van Peteghem C. (1988) 'Detection of oxidatively modified 2¿-deoxyguanosine by means of 32P-postlabeling analysis and anion exchange thin layer chromatography'. Journal of Chromatography-Biomedical Applications, 434 :222. [Details]|
|Rosier J. and Van Peteghem C. (1988) 'Detection of trace amonts of 8-hydroxy-2¿-deoxyguanosine in commercial 2¿-deoxyguanosine by means of serial UV-EC-detection and HPLC analysis'. Journal of Chromatography, 11 (6):1293. [Details]|
|Rosier J. and Van Peteghem C. (1989) 'Peroxidative in vitro metabolism of diethylstilbestrol induces formation of 8-hydroxy-2¿-deoxyguanosine'. Carcinogenesis, 10 :405. [Details]|
|Leonard S., Capote R., Germonprez N., Van Puyvelde L., De Kimpe N., Vermeersch H., J. Rosier, Maes L., Roets E., and Hoogmartens J. (2003) 'Liquid chromatographic method for analysis of saponins in Maesa balansae extract active against leishmaniasis'. Journal of Chromatography, 1012 (12):39. [Details]|
|Leonard S., Van Schepdael A.,*, Iványi T., Lázár I., Rosier J., Vanstockem M., Vermeersch H., Hoogmartens J. (2005) 'Development of a capillary electrophoretic method for the separation of diastereoisomers of a new human immunodeficiency virus protease inhibitor'. Electrophoresis, 26 (3):627. [Details]|
|Baert L., Schueller L., Tardy Y., Macbride D., van¿t Klooster G., Borghys H., Clessens E., Van Den Mooter G., Van Gyseghem E., Van Remoortere P., Wigerinck P. and Rosier J. (2008) 'Development of an implantable infusion pump for sustained anti-HIV drug administration'. International Journal of Pharmaceutics, 355 (2):38. [Details]|
|Schueller L., Baert L., Lachau-Durand S., Borghys H., Clessens E., Van Den Mooter G., Van Gyseghem E., Jonckers T. H.M., Van Remoortere P., Wigerinck P. and Rosier J (2008) 'Dog model with implanted pump to test boosters for antiretroviral medication'. International Journal of Pharmaceutics, 355 (1):45. [Details]|
|Baert L., van ¿t Klooster G., Dries W., François M., Wouters A., Basstanie E., Iterbeke K., Stappers F., Stevens P., Schueller L., Van Remoortere P., Kraus G., Wigerinck P. and Rosier J. (2009) 'Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment'. European Journal of Pharmaceutics and Biopharmaceutics, 72 (3):502. [Details]|
|Gyseghem E., Stokbroekx S., Novoa de Armas H., Dickens J., Vanstockem M., Baert L., Rosier J., Schueller L. and Van den Mooter G. (2009) 'Solid state characterization of the anti-HIV drug TMC114: Interconversion of amorphous TMC114, TMC114 ethanolate and hydrate'. European Journal of Pharmaceutical Science, 38 (5):489. [Details]|
|Thommes M., Baert L., van ¿t Klooster G., Geldof M., Schueller L., Rosier J. and Kleinebudde P. (2009) 'Improved bioavailability of darunavir by use of κ-carrageenan versus microcrystalline cellulose as pelletisation aid'. European Journal of Pharmaceutics and Biopharmaceutics, 72 (3):614. [Details]|
|Van Gyseghem E., Sigrid Stokbroekx S., Hector Novoa de Armas H., Jules Dickens J., Marc Vanstockem M., Lieven Baert L., Jan Rosier J., Laurent Schueller L., Guy Van den Mooter G. (2009) 'Solid state characterization of the anti-HIV drug TMC114: Interconversion of amorphous TMC114, TMC114 ethanolate and hydrate'. European Journal of Pharmaceutical Science, 38 (5):489. [Details]|
|Visser M., Baert L., van ¿t Klooster G., Schueller L., Geldof M., Vanwelkenhuysen I., de Kock H., De Meyer S., W. Frijlink H., Rosier J., L.J. Hinrichs W. (2010) 'Inulin solid dispersion technology to improve the absorption of the BCS Class IV drug TMC240'. European Journal of Pharmaceutics and Biopharmaceutics, 74 (2):233. [Details]|
|Van Gyseghem E., Baert L., Van Remoortere P., van ¿t Klooster G., Rouan M., Voorspoels J., de Kock H., Schueller L., Rosier J., Grooten L. and Van den Mooter G. (2010) 'Co-administration of darunavir and a new pharmacokinetic booster: Formulation strategies and evaluation in dogs'. European Journal of Pharmaceutical Science, 41 (2):193. [Details]|
|Rosier J. and Goffin, K. (2013) 'A systematic review of the literature on the role of the Chief Executive Officer in Innovatio'. International Journal of Management Reviews, . [Details]|
|Rosier J. and Goffin, K. (2013) 'The role of the CEO in innovationin life science R&D firms: the Detection of CEO Absorptive Capacity'. Journal of Product Innovation Management, . [Details]|
|Rosier J., Vanhoorne M., Grosjean R., Van de Walle E. and Billemont G. (1982) 'Preliminary Evaluation of urinary 2-Thio-thiazolidine-4-carboxylic Acid (TTCA) Levels as a test for exposure to Carbon Disulfide' International Archives on Occupational and Environmental Health 51 :159. [Details]|
|Rosier J. and Van Peteghem C. (1983) 'The preparaton of pure 2-Thiothiazolidine-4-Carboxylic Acid as a standard for exposure to carbon disulfde by means of high pressure liquid chromatography' Bulletin des Societes Chimiques Belges 92 :397. [Details]|
|Rosier J., Vanhoorne M. and Van Peteghem C. (1984) 'Historiek en Hedendaagse Trends in de Biologische Monitoring bij Industriële Expositie aan Koolstofdisulfide' Tijdschrift voor Sociale Gezondheidszorg 17 :665. [Details]|
|Rosier J., Vanhoore M., Van De Walle E. and Van Peteghem C. (1984) 'The determination of TTCA levels as a test for exposure to carbon disulfide' Giornale Ital. Med. Lav 6 :119. [Details]|
|Rosier J., Veulemans M., Masschelein R., Vanhoorne M. and Van Peteghem C. (1987) 'Experimental Human Exposure to Carbon Disulfide: I. The Respiratory Uptake and Elimination of Carbon Disulfide under rest and physical exercise' International Archives on Occupational and Environmental Health 59 :223. [Details]|
|Rosier J., Veulemans M., Masschelein R., Vanhoorne M. and Van Peteghem C. (1987) 'Experimental Human Exposure to Carbon Disulfide: II. The urinary excretion of 2-Thio-thiazolidine-4-carboxylic acid during and after exposure to Carbon Disulfide' International Archives on Occupational and Environmental Health 59 :243. [Details]|
|Rosier J. and Van Peteghem C. (1988) 'A screening method for the simultaneous determination of putrescine, cadaverine, histamine, spermidine and spermine in fish by means of high pressure liquid chromatography of their 5-dimethylaminonaphtalene-1-sulphonyl derivatives' Zeitschrift fur Lebensmittel Untersuchung unf Forschung 186 :25. [Details]|
|De Spiegeleer B., Dumont F., Peremans K., Burvenich C., Van Vooren L., Rosier J., Baert L., Wigerinck P., Slegers G (2008) 'Synthesis and HPLC-purification of [77Br]TMC125-R165335 (etravirine), a new anti-HIV drug of the DAPY-NNRTI class' Journal of Labelled Compounds and Radiopharmaceuticals 49 (8) :683. [Details]|
|Thommes M., Baert L., Van t¿ Klooster G., Rosier J. and Kleinebudde P (2008) The bioavailability of Darunavir Pellets using K-Carrageenan as Pelletization Aid American Association for Pharmaceutical Sciences Meeting, Atlanta, USA [Details]|
|Van Gyseghem E., Pendela M., Baert L., Rosier J., Van t¿ Klooster G., De Man H., Bouche M.P., Schueller L., Van Remoorter P., Adams E., Hoogmartens J., Van den Mooter G. (2008) Powder for reconstitution of an anti-HIV-1 drug with low water solubility ¿ formulation development, stability and bioavailability in dogs American Association for Pharmaceutical Sciences Meeting, Atlanta, USA [Details]|
|Rosier J. and Goffin, K. (2013) Exploring the role of the CEO in innovation in life science R&D firms: the detection of CEO absorptive capacity European Institute for the Advanced Study of Management Meeting Paris 2013 [Details]|
I am interested in:
- in the relationship between academic and industrial research. An interesting book that illustrates my interest is 'Evolutionary Innovations, the Business of Biotechnology' by Prof. Maureen McKelvey from the Department of Technology and Social Change at Linköping University. It illustrates the interaction, tensions, disillusions and promises created by bringing academic and industrial research together.
- ways that allow expensive
drugs to become available to all. This is important seen the increasing
complexity of the life sciences and the increasing cost of R&D. I am fascinated by the concept of the Health Impact Fund, developed by
professor Thomas Pogge of Yale University which allows expensive drugs to become
available to the poor such that they can also profit from the research in
the life sciences (see www.HIF.org).
Irish Times Interview - November 21st 2013
An amusing and probably apocryphal story did the rounds of the British research community some years back. It concerned a conversation between a head of research and his managing director and concludes with the research scientist saying to her completely befuddled boss ¿I can explain it for you but I can¿t understand it for you.¿
This is the problem being addressed by Jan Rosier, newly appointed Institute Élan Professor of The Business of Biotechnology, a joint appointment between the UCD College of Science and UCD School of Business.
A former vice president for drug development at Johnson
& Johnson, Prof Rosier's research focuses on the role of chief executives
in innovation in life science R&D firms. Scientists have become so
specialised in their different areas that it is difficult for outsiders to
understand what is going on in those areas, he notes. If you see an article
in Nature or another journal about a new drug or other development in the life
sciences industry you now need a scientific background to read it. I am
interested in how the people at the apex of organisations are going to deal
with that increased level of complexity.¿
Heart of the problem
At the heart of the problem is people from the two areas are effectively speaking different languages ¿ the language of business and finance and the language of science and research.
How are they going to understand each other? Prof Rosier asks. Where is the overlap between their areas? We should be concerned about the possibility that CEOs become spectators in the R&D process. That would not be the wisest thing to allow happen.This can lead to serious problems for companies which rely on research outputs for future success. This is particularly the case in the life sciences and other high tech areas where new product pipelines are critically important. The difficulty lies in the fact that the cheques for the R&D activity have to be written by the CEO and CFO and if these people don't understand what¿s going on in the research department the money is unlikely to be forthcoming or, equally damaging, making it available for the wrong things.It can happen when the corporate strategy is being developed by the CEO and the management team a different strategy is being built in R&D where they are creating competitive knowledge, Rosier explains.
He cites an example given by former Intel ceo Andy Grove in his book Only the Paranoid Survive. ¿He wrote that at one point he and the management developed a strategy but at the same time R&D was developing new products which completely changed that strategy.
But at least Grove and Intel paid attention to what was happening in R&D and acted upon it. Many of the other IT giants competing with Intel in Grove's time no longer exist because they ignored their research departments and failed to keep pace with industry developments
And the price can be even higher with research carried out by Insead in France showing how a major pharmaceutical firm put a drug with known side effects on the market because the managers in overall charge didn¿t understand the information given to them by the research department.
This is why we need to find a way to get these people
talking to each other in a way that is good for innovation, Rosier points out.
Over the past five years he has been carrying out research into the problem and has interviewed life sciences industry ceos and research leaders in the process.
We asked the ceos how they managed innovation and R&D and one of them said he didn¿t understand science and was a bit annoyed by it because it made him feel insecure. Even ceos who had scientific backgrounds felt insecure because the pace of change in the industry meant that once they were out of the lab for a few years they were at a disadvantage to those who stayed in it. What is needed is some kind of a platform or shared space where the two groups can meet.
The R&D people interviewed recognised the problem and the gap in knowledge which exists. ¿They often referred to the issue of trust between them and the ceo and said if they weren¿t trusted they couldn¿t develop the new products needed by the firm. The question is how do you build trust between the two and the R&D people offered part of the solution. They pointed to a need to transform scientific knowledge into a language which could be understood by ceos and other managers.
One solution he is considering is the establishment of new departments in firms to perform this function. ¿Maybe you need a separate department with the people who can confidently translate complex knowledge into a form that can be absorbed by non-scientists and used by top management. I am not arguing that the ceo of a life sciences firm should be a scientist but that they should be able to develop their absorptive capacity to help them understand complex information.
His aim is to create a virtuous circle where the act of making the information understandable to non-scientific people actually assists in the development of their absorptive capacity thereby improving their ability to understand complex information.
By making complex R&D data understandable to the ceo, the ceo develops their capacity to absorb new knowledge and because of their growing understanding of R&D knowledge can develop greater trust in R&D. A knowledge complexity reduction process not only simplifies complex R&D data, but also builds trust, which is the cornerstone of effective leadership.
When the ceo has information they understand they can share it with others and help the organisation achieve its strategic goals much more effectively.
| Sponsor : University College Dublin Foundation Ltd.
Title : Knowledge, learning and absorptive capacities in the context of biotech firms
Start Date / End Date : 03-SEP-14 / 04-SEP-18
| Sponsor : University College Dublin Foundation Ltd.
Title : S007_Elan Chair ¿ NonPay Fund
Start Date / End Date : 01-FEB-15 / 30-SEP-18
|The philosophy of my teaching consists in addressing the diverse components of the landscape of the business of biotechnology in order for the students to obtain a comprehensive view of the management and the science that governs the development of new products.|
| Keith Goffin, Professor of Innovation Management, Center for Innovative Products and Services, Cranfield School of Management, UK
Aidan Hollis, Professor of Economics, University of Calgary, Canada - Global Incentives for Health, The Health Impact Fund (http://www.healthimpactfund.com)